Shanghai RAAS(SZ:002252) Shang Hai Zheng Quan Bao·2025-09-15 20:04Core Viewpoint - The controlling shareholder of Shanghai Laishi Blood Products Co., Ltd., Haiyingkang (Qingdao) Medical Technology Co., Ltd., has successfully completed its shareholding increase plan, demonstrating confidence in the company's future development and long-term investment value [3][9]. Summary by Sections Shareholding Increase Plan - The plan was announced on May 22, 2025, with a commitment to increase shareholding by no less than RMB 250 million and no more than RMB 500 million within six months [3][7]. - The increase was executed through centralized bidding, with a total of 72,935,300 shares acquired, representing 1.10% of the total share capital, for approximately RMB 499.99 million (excluding transaction fees) [9]. Shareholder Information - Prior to the increase, Haiyingkang held 1,474,578,052 shares, accounting for 22.21% of the total share capital, and controlled an additional 437,069,656 shares through voting rights entrusted from Grifols, S.A., totaling 1,911,647,708 shares or 28.80% of the total [4]. Compliance and Commitments - The shareholding increase plan complies with relevant laws and regulations, ensuring that the company's shareholding structure remains within listing requirements [11]. - Haiyingkang has committed not to reduce its shareholding during the increase period and has adhered to regulations regarding insider trading and short-term trading [12].